Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN N HAMILTON

Allopathic & Osteopathic Physicians Urology

NPI
1609965508
CMS profile
408874
Location
GREENVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$40,699.82

132 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN N HAMILTON

NPI 1609965508 · CMS profile ID 408874

Allopathic & Osteopathic Physicians / Urology

GREENVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609965508?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN N HAMILTON, NPI 1609965508, CMS profile ID 408874. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609965508?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JONATHAN N HAMILTON, NPI 1609965508, CMS profile ID 408874. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609965508?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JONATHAN N HAMILTON, NPI 1609965508, CMS profile ID 408874, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–132 of 132 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1609965508?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

132 matching records · $40,699.82 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 132 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–132 of 132.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Dendreon Pharmaceuticals LLC $23.9603/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100361 CMS
Olympus America Inc. $31.7503/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896498047 CMS
Myriad Genetic Laboratories, Inc. $15.2303/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937229665 CMS
Dendreon Pharmaceuticals LLC $27.9403/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100359 CMS
Janssen Biotech, Inc. $15.1803/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886137339 CMS
PFIZER INC. $16.8603/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949078267 CMS
Olympus America Inc. $76.8103/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896498049 CMS
Axonics, Inc. $118.3103/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958531665 CMS
Axonics, Inc. $4.6303/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958531247 CMS
Endo Pharmaceuticals Inc. $15.1503/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929726489 CMS
Dendreon Pharmaceuticals LLC $21.5503/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100357 CMS
Myovant Sciences Inc. $17.9803/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941208389 CMS
Dendreon Pharmaceuticals LLC $1,688.0002/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100355 CMS
Myriad Genetic Laboratories, Inc. $17.5302/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937229661 CMS
Dendreon Pharmaceuticals LLC $21.6402/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100353 CMS
Dendreon Pharmaceuticals LLC $15.7102/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100349 CMS
Dendreon Pharmaceuticals LLC $1,688.0002/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100351 CMS
Bayer HealthCare Pharmaceuticals Inc. $20.4802/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930594141 CMS
Blue Earth Diagnostics Limited $20.4002/15/2022 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 961135333 CMS
Dendreon Pharmaceuticals LLC $20.3302/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100347 CMS
PFIZER INC. $16.7602/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949070143 CMS
ABBVIE INC. $17.5402/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892726765 CMS
Dendreon Pharmaceuticals LLC $17.4301/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100345 CMS
UROVANT SCIENCES INC $17.4501/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 931097261 CMS
Dendreon Pharmaceuticals LLC $17.5701/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100343 CMS
Olympus America Inc. $13.4501/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896498045 CMS
Dendreon Pharmaceuticals LLC $20.7201/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100341 CMS
Dendreon Pharmaceuticals LLC $19.5901/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100339 CMS
UROVANT SCIENCES INC $17.1601/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 931097265 CMS
Dendreon Pharmaceuticals LLC $21.6401/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943100337 CMS
Myriad Genetic Laboratories, Inc. $14.4101/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937229657 CMS
PFIZER INC. $14.9001/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949057277 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $16,160.36 56
PY2020 $4,670.59 24
PY2021 $47,330.54 102
PY2022 $40,699.82 132
PY2023 $57,430.47 130
PY2024 $37,489.64 122
PY2025 $20,149.45 91

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $132,731.82 22
PY2024 Principal investigator $116,395.00 34
PY2023 Principal investigator $77,810.56 13
PY2022 Principal investigator $53,535.36 6
PY2021 Principal investigator $23,394.00 5
PY2020 Principal investigator $37,791.79 7
PY2019 Principal investigator $29,746.68 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $10,058.00 12/29/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175362731
Principal investigator 1 Astellas Pharma Global Development $270.00 11/07/2025 Covered Recipient Teaching Hospital
Pitt County Memorial Hospital Inc
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234180918
Principal investigator 1 Astellas Pharma Global Development $910.00 10/23/2025 Covered Recipient Teaching Hospital
Pitt County Memorial Hospital Inc
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234180916
Principal investigator 1 Janssen Research & Development, LLC $6,788.00 10/02/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) No dispute reported 06/30/2026 1175362720
Principal investigator 1 Janssen Research & Development, LLC $3,270.00 09/08/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362635
Principal investigator 1 Astellas Pharma Global Development $419.00 09/04/2025 Covered Recipient Teaching Hospital
Pitt County Memorial Hospital Inc
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234180914
Principal investigator 1 Janssen Research & Development, LLC $1,759.00 07/28/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362650
Principal investigator 1 Janssen Research & Development, LLC $6,845.00 07/04/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362665
Principal investigator 1 Janssen Research & Development, LLC $2,572.72 06/23/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175362673
Principal investigator 1 Janssen Research & Development, LLC $29,206.19 06/23/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175362749
Principal investigator 1 Janssen Research & Development, LLC $4,137.00 06/06/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca No dispute reported 06/30/2026 1175362702
Principal investigator 1 Janssen Research & Development, LLC $1,759.00 04/28/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362643
Principal investigator 1 Janssen Research & Development, LLC $31,778.91 04/21/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362680
Principal investigator 1 Janssen Research & Development, LLC $6,449.00 04/07/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362742
Principal investigator 1 Janssen Research & Development, LLC $4,056.00 03/20/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362693
Principal investigator 1 Astellas Pharma Global Development $565.00 03/19/2025 Covered Recipient Teaching Hospital
Pitt County Memorial Hospital Inc
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234180912
Principal investigator 1 Janssen Research & Development, LLC $2,305.00 03/13/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362627
Principal investigator 1 Janssen Research & Development, LLC $4,104.00 03/10/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362657
Principal investigator 1 Janssen Research & Development, LLC $3,054.00 03/06/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362687
Principal investigator 1 Janssen Research & Development, LLC $1,981.00 03/06/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362757
Principal investigator 1 Janssen Research & Development, LLC $6,357.00 02/10/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362711
Principal investigator 1 Janssen Research & Development, LLC $4,088.00 01/02/2025 Non-covered Recipient Entity
VIDANT MEDICAL GROUP LLC DBA ECU HE ALTH UROLOGY GREENVILLE
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc No dispute reported 06/30/2026 1175362619